Shanghai Pharmaceuticals Valuation
| 601607 Stock | 19.11 0.31 1.60% |
At this time, the company appears to be overvalued. Shanghai Pharmaceuticals has a current Real Value of USD16.46 per share. The regular price of the company is USD19.11. Our model measures the value of Shanghai Pharmaceuticals from inspecting the company fundamentals such as Return On Equity of 0.0716, operating margin of 0.04 %, and Shares Outstanding of 2.79 B as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 0.9887 | Enterprise Value 67.2 B | Enterprise Value Ebitda 5.467 | Price Sales 0.2312 | Forward PE 16.2075 |
Overvalued
Today
Please note that Shanghai Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Shanghai Pharmaceuticals is based on 3 months time horizon. Increasing Shanghai Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Shanghai Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Shanghai Stock. However, Shanghai Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.11 | Real 16.46 | Hype 19.18 | Naive 19.29 |
The real value of Shanghai Stock, also known as its intrinsic value, is the underlying worth of Shanghai Pharmaceuticals Company, which is reflected in its stock price. It is based on Shanghai Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Shanghai Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Shanghai Pharmaceuticals Holding helps investors to forecast how Shanghai stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Shanghai Pharmaceuticals more accurately as focusing exclusively on Shanghai Pharmaceuticals' fundamentals will not take into account other important factors: Shanghai Pharmaceuticals Cash |
|
Shanghai Pharmaceuticals Total Value Analysis
Shanghai Pharmaceuticals Holding is presently forecasted to have takeover price of 67.22 B with market capitalization of 63.65 B, debt of 38.06 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Shanghai Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
67.22 B | 63.65 B | 38.06 B |
Shanghai Pharmaceuticals Investor Information
About 65.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 0.99. In the past many companies with similar price-to-book ratios have beat the market. Shanghai Pharmaceuticals last dividend was issued on the 24th of September 2024. The entity had 1.2:1 split on the 16th of August 2007. Based on the key indicators related to Shanghai Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Shanghai Pharmaceuticals Holding is performing exceptionally good at this time. It has a great probability to report excellent financial results in April.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 6.1 B | 5.8 B |
|
| |||||
| Operating Income | 10.2 B | 9.7 B |
|
|
Shanghai Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Shanghai Pharmaceuticals has an asset utilization ratio of 124.43 percent. This suggests that the Company is making USD1.24 for each dollar of assets. An increasing asset utilization means that Shanghai Pharmaceuticals Holding is more efficient with each dollar of assets it utilizes for everyday operations.Shanghai Pharmaceuticals Ownership Allocation
Shanghai Pharmaceuticals shows a total of 2.79 Billion outstanding shares. Shanghai Pharmaceuticals has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.98 % of Shanghai Pharmaceuticals outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Shanghai Pharmaceuticals Profitability Analysis
The company reported the revenue of 275.25 B. Net Income was 4.55 B with profit before overhead, payroll, taxes, and interest of 30.63 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Shanghai Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Shanghai Pharmaceuticals and how it compares across the competition.
About Shanghai Pharmaceuticals Valuation
The stock valuation mechanism determines Shanghai Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Shanghai Pharmaceuticals. We calculate exposure to Shanghai Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Shanghai Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 30.6 B | 26.5 B |
Shanghai Pharmaceuticals Quarterly Retained Earnings |
|
Complementary Tools for Shanghai Stock analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |